145 related articles for article (PubMed ID: 34590021)
1. Malignant Pleural Mesothelioma-Does Ki67 Make the Grade?
Prall OWJ
JTO Clin Res Rep; 2021 May; 2(5):100170. PubMed ID: 34590021
[No Abstract] [Full Text] [Related]
2. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
Pezzuto F; Vimercati L; Fortarezza F; Marzullo A; Pennella A; Cavone D; Punzi A; Caporusso C; d'Amati A; Lettini T; Serio G
Diagn Pathol; 2021 Jul; 16(1):64. PubMed ID: 34294087
[TBL] [Abstract][Full Text] [Related]
3. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
Ghanim B; Klikovits T; Hoda MA; Lang G; Szirtes I; Setinek U; Rozsas A; Renyi-Vamos F; Laszlo V; Grusch M; Filipits M; Scheed A; Jakopovic M; Samarzija M; Brcic L; Stancic-Rokotov D; Kern I; Rozman A; Dekan G; Klepetko W; Berger W; Glasz T; Dome B; Hegedus B
Br J Cancer; 2015 Mar; 112(5):783-92. PubMed ID: 25633038
[TBL] [Abstract][Full Text] [Related]
4. Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.
Rosen LE; Karrison T; Ananthanarayanan V; Gallan AJ; Adusumilli PS; Alchami FS; Attanoos R; Brcic L; Butnor KJ; Galateau-Sallé F; Hiroshima K; Kadota K; Klampatsa A; Stang NL; Lindenmann J; Litzky LA; Marchevsky A; Medeiros F; Montero MA; Moore DA; Nabeshima K; Pavlisko EN; Roggli VL; Sauter JL; Sharma A; Sheaff M; Travis WD; Vigneswaran WT; Vrugt B; Walts AE; Tjota MY; Krausz T; Husain AN
Mod Pathol; 2018 Apr; 31(4):598-606. PubMed ID: 29327706
[TBL] [Abstract][Full Text] [Related]
5. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
[TBL] [Abstract][Full Text] [Related]
6. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Alley EW; Lopez J; Santoro A; Morosky A; Saraf S; Piperdi B; van Brummelen E
Lancet Oncol; 2017 May; 18(5):623-630. PubMed ID: 28291584
[TBL] [Abstract][Full Text] [Related]
7. [Updates in the pathological diagnosis of Pleural Malignant Mesothelioma in the WHO classification of thoracic tumors (5(th) edition)].
Piao ZH; Zhou XC; Zhang X
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2022 Dec; 40(12):956-960. PubMed ID: 36646495
[TBL] [Abstract][Full Text] [Related]
8. Malignant and non-malignant asbestos-related pleural and lung disease: 10-year follow-up study.
Cvitanović S; Znaor L; Konsa T; Ivancević Z; Perić I; Erceg M; Vujović M; Vuković J; Beg-Zec Z
Croat Med J; 2003 Oct; 44(5):618-25. PubMed ID: 14515425
[TBL] [Abstract][Full Text] [Related]
9. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.
Kadota K; Suzuki K; Colovos C; Sima CS; Rusch VW; Travis WD; Adusumilli PS
Mod Pathol; 2012 Feb; 25(2):260-71. PubMed ID: 21983936
[TBL] [Abstract][Full Text] [Related]
10. Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma.
Belderbos RA; Maat APWM; Baart SJ; Madsen EVE; Bogers AJJC; Cornelissen R; Aerts JGJV; Mahtab EAF; von der Thüsen JH
JTO Clin Res Rep; 2021 Apr; 2(4):100155. PubMed ID: 34590009
[TBL] [Abstract][Full Text] [Related]
11. [Helical tomotherapy in the treatment of malignant pleural mesothelioma: The impact of low doses on pulmonary and oesophageal toxicity].
Helou J; Clément-Colmou K; Sylvestre A; Campion L; Amessis M; Zefkili S; Raphael J; Bonnette P; Le Pimpec Barthes F; Périgaud C; Mahé MA; Giraud P
Cancer Radiother; 2013 Dec; 17(8):755-62. PubMed ID: 24269017
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.
Steele JP; O'Doherty CA; Shamash J; Evans MT; Gower NH; Tischkowitz MD; Rudd RM
Ann Oncol; 2001 Apr; 12(4):497-9. PubMed ID: 11398882
[TBL] [Abstract][Full Text] [Related]
13. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
Zauderer MG; Szlosarek PW; Le Moulec S; Popat S; Taylor P; Planchard D; Scherpereel A; Koczywas M; Forster M; Cameron RB; Peikert T; Argon EK; Michaud NR; Szanto A; Yang J; Chen Y; Kansra V; Agarwal S; Fennell DA
Lancet Oncol; 2022 Jun; 23(6):758-767. PubMed ID: 35588752
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial.
Clive AO; Taylor H; Dobson L; Wilson P; de Winton E; Panakis N; Pepperell J; Howell T; Stewart SA; Penz E; Jordan N; Morley AJ; Zahan-Evans N; Smith S; Batchelor TJP; Marchbank A; Bishop L; Ionescu AA; Bayne M; Cooper S; Kerry A; Jenkins P; Toy E; Vigneswaran V; Gildersleve J; Ahmed M; McDonald F; Button M; Lewanski C; Comins C; Dakshinamoorthy M; Lee YCG; Rahman NM; Maskell NA
Lancet Oncol; 2016 Aug; 17(8):1094-1104. PubMed ID: 27345639
[TBL] [Abstract][Full Text] [Related]
15. High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment.
Parisi E; Romeo A; Sarnelli A; Ghigi G; Bellia SR; Neri E; Micheletti S; Dipalma B; Arpa D; Furini G; Burgio MA; Genestreti G; Gurioli C; Sanna S; Bovolato P; Rea F; Storme G; Scarpi E; Arienti C; Tesei A; Polico R
Cancer Radiother; 2017 Dec; 21(8):766-773. PubMed ID: 29132803
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
17. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
Castagneto B; Zai S; Mutti L; Lazzaro A; Ridolfi R; Piccolini E; Ardizzoni A; Fumagalli L; Valsuani G; Botta M
Lung Cancer; 2001; 31(2-3):303-10. PubMed ID: 11165411
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile.
Nakano T; Chahinian AP; Shinjo M; Togawa N; Tonomura A; Miyake M; Ninomiya K; Yamamoto T; Higashino K
Cancer; 1999 Jun; 85(11):2375-84. PubMed ID: 10357408
[TBL] [Abstract][Full Text] [Related]
19. [Prophylactic radiotherapy in a single fraction of 10Gy at intervention pleural site in patient with malignant pleural mesothelioma: A retrospective monocentric cohort study].
Carette H; Faivre JC; Salleron J; Baumann AS; Uwer L; Clément-Duchêne C; Vignaud JM; Petit I; Siat J; Tiotiu A; Beckendorf V
Cancer Radiother; 2017 Dec; 21(8):774-783. PubMed ID: 29132802
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Ki67 Percentage, WT-1 Expression and p16/CDKN2A Deletion in Diffuse Malignant Peritoneal Mesothelioma: A Single-Centre Cohort Study.
Pezzuto F; Serio G; Fortarezza F; Scattone A; Caporusso C; Punzi A; Cavone D; Pennella A; Marzullo A; Vimercati L
Diagnostics (Basel); 2020 Jun; 10(6):. PubMed ID: 32526924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
